US00653A1079 - ADR
ADAPTIMMUNE THERAPEUTICS-ADR
NASDAQ:ADAP (4/19/2024, 7:00:00 PM)
After market: 0.98 +0 (+0.34%)0.9767
+0.08 (+8.72%)
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Abingdon, Oxfordshire and currently employs 534 full-time employees. The company went IPO on 2015-05-06. The firm is focused on providing cell therapies to people with cancer. The company develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).
ADAPTIMMUNE THERAPEUTICS-ADR
60 Jubilee Avenue
Abingdon OXFORDSHIRE OX14 4RX
P: 441235430000
CEO: Adrian Rawcliffe
Employees: 534
Website: https://www.adaptimmune.com/
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adaptimmune Therapeutics (NASDAQ:ADAP) just reported results for the fourth qua...
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Here you can normally see the latest stock twits on ADAP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: